The′immunologic advantage′ of HIV-exposed seronegative individuals

AIDS

Volumn 23, Issue 2, 2009, Pages 161-175

  Miyazawa, Masaaki ^a   Lopalco, Lucia ^b   Mazzotta, Francesco ^c   Caputo, Sergio Lo ^c   Veas, Francisco ^d   Clerici, Mario ^e,f  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY OF MILAN   (Italy)

^f IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD4 ANTIBODY; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 22; MANNOSE BINDING LECTIN; VITAMIN D RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE PREDISPOSITION; EDITORIAL; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INNATE IMMUNITY; PHENOTYPE; PRIORITY JOURNAL; SEROLOGY; VIRUS GENOME; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; NOMENCLATURE; SERODIAGNOSIS;

DISEASE SUSCEPTIBILITY; HIV ANTIBODIES; HIV SERONEGATIVITY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; TERMINOLOGY AS TOPIC;

EID: 58949097921     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283196a80     Document Type: Editorial

References (170)

1. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdevirta J, et al. T cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV exposed sexual partners. AIDS 1989; 3:63-69.
2. Clerici M, Berzofsky JA, Shearer GM, Tackett CO. HIV-1 exposure indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. j Infect Dis 1991; 164:178-182.
3. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. j Infect Dis 1992; 165:1012-1019.
4. Clerici M, Sison AV, Berzofsky JA, Rakusan TA, Brandt CD, Ellaurie M, et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 1993; 7:1427- 1435.
5. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in HIV seronegative healthcare workers accidentally exposed to HIV-contaminated blood. JAMA 1994; 271:42-46.
6. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 7:21-24.
7. Fowke KR, Nagelkerke NJD, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347-1351.
8. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993; 341:860- 861.
9. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
10. Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-1035.
11. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, QuiIlent C, et al.Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. j Exp Med 1997; 186:455-460.
12. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. j Infect Dis 1998; 177:470-472.
13. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV- seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3:1250-1257.
14. Lo Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa ML, et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003; 17:531-539.
15. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users.) Immunol 2003; 171:5663-5667.
16. De Maria A, Cirillo C, Moretta L. Occurrence of HIV-1 specific cytolytic T cell activity in apparently uninfected children born to HIV-1 infected mothers. j Infect Dis 1994; 170:1296-1303.
17. Langlade-Demoyen P, Ngo-Giang-Huong F, Ferchal F. Oksenhendler E. HIV-nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV infected patients. j Clin Invest 1994; 93:1297-1307.
18. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative healthcare workers occupational exposed to HIV-contaminated body fluids. j Clin Invest 1995; 96:867-876.
19. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. j Clin Invest 1998; 102:1758-1765.
20. Kelker HC, Seidlin M, Vogler M, Valentine FT. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses 1992; 8:1355-1359.
21. Goh WC, Markee J, Akridge RE, Meldorf M, Musey L, Karchmer T, et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179: 548-557.
22. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. j Infect Dis 2002; 185:428-438.
23. Suresh P, Wanchu A, Bhatnagar A, Sachdeva RK, Sharma M. Spontaneous and antigen-induced chemokine production in exposed but uninfected partners of HIV type 1 -infected individuals in North India. AIDS Res Hum Retroviruses 2007; 23:261-268.
24. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
25. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? j Clin Immunol 1999; 19:293-299.
26. Biasin M, Caputo SL, Speciale L, Colombo F, Racioppi L, Zagliani A, et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. j Infect Dis 2000; 182:1365-1374.
27. Promadej N, Costello C, Wernett MM, Kulkami PS, Robison VA, Nelson KE, et al. Broad human immunodeficiency virus (HlV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV- infected partner. j Infect Dis 2003; 187:1053-1063.
28. Jennes W, Vuylsteke B, Borget MY, Traore-Ettiegne V, Maurice C, Nolan M, et al. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'lvoire. j Infect Dis 2004; 189:602-610.
29. Kebba A, Kaleebu P, Rowland S, Ingram R, Whitworth J, Imami N, et al. Distinct patterns of peripheral HIV-1-specific inter- feron-gamma responses in exposed HIV-1-seronegative individuals. j Infect Dis 2004; 189:1 705-1 713.
30. Hladik F, Desbien A, Lang J, Wang L, Ding Y, Holte S, et al. Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secretingTcells.J lmmunol 2003; 171:2671-2683.
31. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120:138-146.
32. Jennes W, Sawadogo S, Koblavi-Deme S, Vuylsteke B, Maurice C, Roels TH, et al. Cellular human immunodeficiency virus (HlV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Cote d'lvoire. j Infect Dis 2003; 187:206-214.
33. Schenal M, Lo Caputo S, Fasano F, Vichi F, Saresella M, Pierotti P, et al. Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. AIDS 2005; 19:653-661.
34. Tran HK, Chartier L, Troung LX, Nguyen NN, Fontanet A, Barre-Sinoussi FE, et al. Systemic immune activation in HIV-1- exposed uninfected Vietnamese intravascular drug users. AIDS Res Hum Retrovir 2006; 22:255-261.
35. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS ONE 2006; 1:e102. doi: 10.1371/journal.pone.0000102.
36. Alimonti JB, Kimani J, Matu L, Wachihi C, Kaul R, Plummer FA, et al. Characterization of CD8 T-cell responses in HIV-1- exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol 2006; 84:482-485.
37. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164:1602-1611.
38. Makedonas G, Bruneau J, Lin H, Sekaly RP, Lamothe F, Bernard NF. HIV-specific CD8+ T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. AIDS 2002; 16:1595-1602.
39. John R, Arango-Jaramillo S, Finny GJ, Schwartz DH. Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5. j Acquir Immune Defic Syndr 2004; 35:1-8.
40. Pallikkuth S, Wanchu A, Bhatnagar A, Sachdeva RK, Sharma M. Human immunodeficiency virus (HIV) gag antigen- specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India. Clin Vaccine Immunol 2007; 14:1196-1202.
41. Rock KL, York lA, Saric T, Goldberg AL. Protein degradation and the generation of class l-presented antigens. Adv Immunol 2002; 80:1-70.
42. Reimann J, Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class l-restricted presentation. Immunol Rev 1999; 172:131-152.
43. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects. j Clin Invest 2001; 107:1303-1310.
44. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, et al. Human immunodeficiency virus (HIV)- specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. j Infect Dis 1999; 180:871-875.
45. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite preexisting HIV-specific CD8+ responses. j Clin Invest 2001; 107:341-349.
46. Bernard NF, Yannakis CM, Lee JS, Tsoukas CM. Human immunodeficiency virus (HlV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. j Infect Dis 1999; 179:538-547.
47. Bègaud E, Chartier L, Marechal V, Ipero J, Leal J, Versmisse P, et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006; 3:35.
48. Jennes W, Evertse D, Borget MY, Vuylsteke B, Maurice C, Nkengasong JN, et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol 2006; 143:435-444.
49. Suy A, Castro P, Nomdedeu M, García F, López A, Fumero E, et al. Immunological profile of heterosexual highly HIV- exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. j Infect Dis 2007; 196: 1191-1201.
50. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996; 17:217-224.
51. Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628-632.
52. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187-191.
53. Shapira-Nahor O, Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Shapiro M, et al. Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals. AIDS 1998; 12:1731- 1733.
54. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, Kityo C, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. j Infect Dis 2005; 191: 694-701.
55. Dorsett B, Cronin W, Chuma V, loachim HL. Antilymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am j Medicine 1985; 78:621-626.
56. Daniel V, Schimpf K, Opelz G. Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol 1989; 75:1 78-183.
57. BorghiMO, De Santis C, Barcellini W, Lopalco L, Fain C, et al. Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. j AIDS 1993; 6:1114-1119.
58. Blanton M, Balakrishnan K, Dumaswala U, Zelenski K, Greenwalt TJ. HLA antibodies in blood donors with reactive screening tests for antibody to the immunodeficiency virus. Transfusion 1987; 27:118-119.
59. Riera NE, Galassi N, de la Barrera S, Rickard E, Muchinik G, Perez-Bianco R, de Bracco MM. Antileukocyte antibodies as a consequence of HIV infection in HIV+ individuals. Immunol Lett 1992; 33:99-104.
60. Beretta A, Weiss SH, Rappocciolo G, Mayur R, De Santis C, Quirinale J, et al. Human immunodeficiency virus type 1 (HIV-1-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996; 173: 472-476.
61. Burastero SE, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, De Santis C, et al. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retrovir 1996; 12:273-280.
62. Lopalco L, Pastori C, Cosma A, Burastero SE, Capiluppi B, Boeri E, et al. Anticell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retrovir 2000; 16:109-115.
63. Lopalco L, Magnani Z, Confetti C, Brianza M, Saracco A, Ferraris G, et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. AIDS Res Hum Retrovir 1999; 15:1079-1085.
64. Callahan LN, Roderiquez G, Mallinson M, Norcross MA. Analysis of HIV-induced autoantibodies to cryptic epitopes on human CD4. J Immunol 1992; 149:2194-2202.
65. Furci L, Beretta A, Siccardi A, Lazzarin A, Confetti C, Magnani Z, et al. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermodular help for anti-CD4 autoantibody production in exposed uninfected subjects. AIDS Res Hum Retrovir 1997; 13:1461-1469.
66. Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. I Immunol 2000; 164:3426-3433.
67. Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, Longhi R, et al. CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression. Blood 2006; 107:4825-4833.
68. Margolis L, Shattock R. Selective transmission of CCR5- utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 2006; 4:313-318.
69. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, Nguyen M, et al. Predictive value of anticell and antihuman immunodeficiency virus (HIV) humoral responses in HIV-1- exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005; 86:339-348.
70. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 1996; 10:1535-1542.
71. Rizzardini G, Trabattoni D, Saresella M, Piconi S, Lukwiya M, Declich S, et al. Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS 1998; 12:2387-2396.
72. Clerici M, Butto S, Lukwiya M, Saresella M, Declich S, Trabattoni D, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000; 14:2083-2092.
73. Ditzel HJ, Rosenkilde MM, Garred P, Wang M, Koefoed K, Pedersen C, et al. The CCR5 receptor acts as an alloantigen in CCR5 Delta32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A 1998; 95:5241-5245.
74. Bouhlal H, Hocini H, Quillent-Gregoire C, Donkova V, Rose S, Amara A, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166:7606-7611.
75. Bouhlal H, Latry V, Requena M, Aubry S, Kaveri SV, Kazatchkine MD, et al. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol 2005; 174:7202-7209.
76. Eslahpazir J, Jenabian M, Bouhlal H, Hocini H, Carbonneil C, Gresenguet G, et al. Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vacc Immunol 2008; 15:872-874.
77. Russo S, Lopalco L. Is autoimmunity a component of natural immunity to HIV? Curr HIV Res 2006; 4:1 77-190.
78. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1:329-337.
79. de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, Beretta A. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retrovir 1994; 10:157-162.
80. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906-1908.
81. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007; 178:4424-4435.
82. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: an hypothesis. Hum Antibodies 2005; 14:59-67.
83. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161- 2170.
84. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007; 21:2131- 2139.
85. Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3:217- 228.
86. Outlaw MC, Armstrong SJ, Dimmock NJ. Mechanisms of neutralization of influenza virus in tracheal epithelial and BHK cells vary according to IgG concentration. Virology 1990; 178:478-485.
87. Robert-Guroff M. IgG surfaces as an important component in mucosal protection. Nat Med 2000; 6:129-130.
88. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272:104-107.
89. Krause RM, Dimmock NJ, Morens DM. Summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997; 176:549-559.
90. van Egmond M, Damen CA, van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JG. IgA and the IgA Fc receptor. Trends Immunol 2001; 22:205-211.
91. Belec L, Ghys PD, Hocini H, NkengasongJN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to HIV type 1 that block viral transcytosis through epithelial barriers in highly exposed HIV-1 - seronegative African women. J Infect Dis 2001; 184:1412-1422.
92. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti HIV envelope protein dlgA or IgM. Immunity 1998; 9:277-287.
93. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood 2004; 104:2205-2206.
94. Wanchu A, Sachdev R, Bagga R. HIV-1 gag-specific mucosal antibodies in a cohort of exposed but uninfected heterosexual partners of HIV-1-infected Individuals in north India. CROI 2008; Boston, MA, USA; 3-6 February 2008, abstract 430.
95. Kaul R, Trabattoni D, BwayoJJ, Arienti D, Zagliana A, Mwangi FM, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1- resistant Kenyan sex workers. AIDS 1999; 13:23-29.
96. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, et al. HIV-neutralizing IgA and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008; 22:727-735.
97. Beyrer C, Artenstein AW, RugPao S, Stephens H, VanCott TC, Robb ML, et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J Infect Dis 1999; 179:59-67.
98. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ing R, et al. HIV specific antibodies but not T cell responses are associated to protection in seronegative partners of HIV infected individuals in Cambodia. J AIDS 2006; 42:412-419.
99. Ghys PD, Belec L, Diallo MO, Ettiegne-Traore V, Becquart P, Maurice C, et al. Cervicovaginal anti-HIV antibodies in HIV- seronegative female sex workers in Abidjan, Cote d'lvoire. AIDS 2000; 14:2603-2608.
100. Buchacz K, Parekh BS, Padian NS, Van Der Straten A, Phillips S, Jonte J, Holmberg SD. HlV-specific IgG in cervicovaginal secretions of exposed HlV-uninfected female sexual partners of HIV infected men. AIDS Res Hum Retrovir 2001; 17:1689- 1693.
101. Farquhar C, VanCott T, Bosire R, Bermudez C, Mbori-Ngacha D, Lohman-Payne B, et al. Salivary human HlV-specific immunoglobulin A in HIV-1 -exposed infants in Kenya. Clin Exp Immunol 2008; 153:37-43.
102. + T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions. J Exp Med 2003; 198:1011-1021.
103. Gardby E, Wrammert J, Schon K, Ekman L, Leanderson T, et al. Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant. J Immunol 2003; 170:55-63.
104. Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, et al. Human dendritic cells skew isotype switching of CD40- activated naive B cells towards lgA1 and lgA2. J Exp Med 1997; 185:1909-1918.
105. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha- helix of gp41. AIDS 2002; 16:1731-1741.
106. Lopalco L, Longhi R, Ciccomascolo F, De Rossi A, Pelagi M, Andronico F, et al. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS Res Hum Retrovir 1993; 9:33-39.
107. Devito C, Hinkula J, Kaul R, Lopalco L, BwayoJJ, Plummer FA, et al. Mucosal IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917-1920.
108. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, etal. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J AIDS 2002; 30:413-420.
109. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165:5170-5176.
110. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001 ; 166:6257-6626.
111. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae- associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003; 170:3799-3805.
112. Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, Kanamaru A, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 2004; 173:3668-3675.
113. Castelletti E, LoCaputoS, Kuhn L, Borelli M, Gajardo J, Sinkala M, et al. The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS ONE 2007; 2:e969; doi: 10.1371/journal.pone.0000969.
114. Buchacz K, Parekh BS, Padian NS, Van der Straten A, Phillips S, Jonte J, Holmberg SD. HlV-specific IgG in cervicovaginal secretions of exposed HlV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retrovir 2001;17:1689- 1693.
115. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland- Jones S, et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14:1117-1122.
116. Jackson S, Prince S, Kulhavy R, Mestecky J. False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens. AIDS Res Hum Retrovir 2000; 16:595-602.
117. Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, VanCott TC, et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retrovir 2002; 18:1291-1300.
118. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996; 104:538-542.
119. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262:44-58.
120. Becquart P, Hocini H, Levy M, Sepou A, Kazatchkine D, Belec L. Secretory antihuman immunodeficiency virus (HIV) antibodies in colostrums and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000; 181:532-539.
121. Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, et al. HlV-specific secretory IgA in breast milk of HIV- positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 2006; 149: 611-616.
122. Giavendoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodora VL. Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus.J Virol 2000; 74:1648-1657.
123. Kittilil S, Chun T-W, Mori S, Liu M, McLaughlin C, et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis 2003; 187:1038-1045.
124. Bruunsgaart H, Pedersen C, Skinhøj P, Pedersen BK. Clinical progression of HIV infection: role of NK cells. Scad J Immunol 1997; 46:91-95.
125. jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, et al. Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177:6588-6592.
126. Boulet S, Sharafi S, Simic N, Bruneau j, Routy J-P, et al. Increased proportion of KIR3DS1 homozygotes in HIV- exposed uninfected individuals. AIDS 2008; 22:595- 599.
127. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, et al. Distinctive NK-cell receptor repertoires sustain high- level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305.
128. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429- 434.
129. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, Simic N, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
130. Chiu YL, Greene WC. Multifaceted antiviral actions of APO- BEC3 cytidine deaminases. Trends Immunol 2006; 27:291- 297.
131. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195:960-964.
132. Oliva H, Montserrat P, Lopez A, Martinez-Navio J, Franco R, Miro' J, et al. APOBEC3G protein expression in blood resting and activated CD4+ and CD8+ T cells. Its effect on susceptibility to HIV infection and progression. CROI 2008; Boston, MA, USA; 3-6 February 2008, abstract 212.
133. Misse D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. j Immunol 2007; 178:407-415.
134. Yang C, Li M, Limpakarnjanarat K, Young NL, Hodge T, Butera ST, et al. Polymorphisms in the CCRS coding and noncoding regions among HIV type 1 -exposed, persistently seronegative female sex-workers from Thailand. AIDS Res Hum Retrovir 2003; 19:661-665.
135. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, et al. HlV-specific cytotoxic T lymphocytes, HLA-All, and chemokine-related factors may act synergis- tically to determine HIV resistance in CCR5Δ32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retrovir 2001; 17:719-734.
136. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959-965.
137. Louisirirotchanakul S, Liu H, Roongpisuthipong A, Nakayama EE, Takebe Y, Shioda T, Wasi C. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2-64I homozygosity with HIV-1-negative status. J Acquir Immune Defic Syndr 2002; 29:314-315.
138. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N, et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RAIMTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004; 190:1055-1058.
139. Winkler C, Modi W, Smith MW, Nelson CW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389- 393.
140. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349:236-240.
141. Mombo LE, Lu CY, Ossari S, Bedjabaga I, Sica L, Krishnamoorthy R, et al. Mannose-binding lectin alleles in sub-Saharan Africans and relation with susceptibility to infections. Cenes Immun 2003; 4:362-367.
142. Wichukchinda N, Kitamura Y, Rojanawiwat A, Nakayama EE, Song H, Pathipvanich P, et al. The polymorphisms in DC- SIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retrovir 2007; 23:686-692.
143. de la Torre MS, Torres C, Nieto G, Vergara S, Carrero AJ, Macias j, et al. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. j Infect Dis 2008; 197:405-410.
144. Ball TB, Ji HZ, Kimani J, McLaren P, Marlin C, Hill AVS, et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007; 21:1091-1101.
145. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
146. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Med 2007; 8:1324-1336.
147. Kuhn L, Schramm DB, Donninger S, Meddows-Taylor S, Coovadia AH, Sherman GG, et al. African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS 2007; 21:1753-1761.
148. Pilotti E, Elviri L, Vicenzi E, Bertazzoni U, Re MC, Allibardi S, et al. Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007; 109:1850-1856.
149. Hardie RA, Luo M, Bruneau B, Knight E, Nagelkerke NJ, Kimani j, et al. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 2008; 22:807-816.
150. MacDonald KS, EmbreeJ, Njenga S, Nagelkerke NJD, Ngatia I, Mohammed Z, et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. j Infect Dis 1998; 177:551-556.
151. Kanari Y, Clerici M, Abe H, Kawabata H, Trabattoni D, Lo Caputo S, et al. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS 2005; 19:1015-1024.
152. Cole AM, Cole AL. Antimicrobial polypeptides are key anti- HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27-34.
153. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, Selsted ME, Levy JA. α-Defensins can have anti-HIV activity but are not CD8+ cell anti-HIV factors. AIDS 2003; 17.F23-F32.
154. Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learnt from studies of highly exposed persistently serogenative (HEPS) individuals. AIDS Rev 2003; 5:87- 103.
155. Soriano A, Martinez C, Garcia F, Plana M, Palou E, Lejeune M, et al. Plasma stromal cell-derived factor (SDFj-1 levels, SDF1- 3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. j Infect Dis 2002; 186:922-931
156. Malik S, Arias M, Di Flumeri C, Garcia LF, Schurr E. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Immunogenetics 2003; 55:49-52.
157. Marquet S, Sanchez FO, Arias M, Rodriguez J, Paris SC, Skamene E, et al. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility. j Infect Dis 1999; 180:1521-1525.
158. Chesebro B, Miyazawa M, Britt WJ. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 1990; 8:477- 499.
159. Miyazawa M. Host genes that influence immune and nonimmune resistance mechanisms against retrovrial infections. Recent Res Dev Virol 2004; 6:105-118; 2004.
160. Miyazawa M, Tsuji-Kawahara S, Kanari Y. Host genetic factors that control immune responses to retrovirus infections. Vaccine 2008. doi: 10.1016/j.vaccine.2008.01.004.
161. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
162. Carrington M, Bontrop RE. Effects of MHC class I on HIV/SIV disease in primates. AIDS 2002; 16 (Suppl 4):S105-S114.
163. Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, et al. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. j Immunol 1995; 155:748-758.
164. + T cell-deficient mice against Friend retrovirus- induced disease. Int Immunol 2006; 18:183-198.
165. Iwanami N, Niwa A, Yasutomi Y, Tabata N, Miyazawa M. Role of natural killer cells in resistance against Friend retrovirus- induced leukemia. J Virol 2001; 75:3152-3163.
166. Takeda E, Tsuji-Kawahara S, Sakamotol M, Langlois M-A, Neuberger MS, Rada C, etal. Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo. j Virol 2008. [Epub ahead of print].
167. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008; 321:1343-1346.
168. Clerici M, Shearer GM. Is HIV infection associated with a TH1→ TH2 switch? Immunol Today 1993; 14:107-111.
169. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM. A strategy for prophylactic vaccination against HIV. Science 1993; 260:1270-1272.
170. Lehner T, Wang YF, Cranage M, Bergmeier LA, Mitchell E, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2:767- 775.